Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CervoMed Inc.DFFN · Entity 7338 | Director | June 30, 2023 | July 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CervoMed Inc.
Report date June 30, 2023 · Filed July 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 294 |
Ending reported balance
After 2023-06-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-06-30 · Exercise / conversion · Acquired 232 · Balance 379 F1: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 147 Shares and (ii) $283.90 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.34. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Row 2 · 2023-06-30 · Disposition to issuer · Disposed 85 · Balance 294 F1: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 147 Shares and (ii) $283.90 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.34. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 928 |
Reported balance
After 2023-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-30 · Exercise / conversion · Disposed 232 · Balance 928 F1: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 147 Shares and (ii) $283.90 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.34. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 147 Shares and (ii) $283.90 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.34. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2023 Filed Jul 5, 2023 21:30 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionRestricted Stock Unit · Derivative | 232 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-019395 · rdgdoc.xml · derivative · entry 3 LANCHONEY DIANA M · CIK 0001887450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 928 Underlying: Common Stock · 232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 147 Shares and (ii) $283.90 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.34. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.exercise_date: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 147 Shares and (ii) $283.90 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.34. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 147 Shares and (ii) $283.90 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.34. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:30 UTC | CervoMed Inc. DFFN · Entity 7338 | Disposition to issuerCommon Stock | 85 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-019395 · rdgdoc.xml · nonDerivative · entry 2 LANCHONEY DIANA M · CIK 0001887450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294 F1 · kind: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 147 Shares and (ii) $283.90 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.34. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · price: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 147 Shares and (ii) $283.90 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.34. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:30 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionCommon Stock | 232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-019395 · rdgdoc.xml · nonDerivative · entry 1 LANCHONEY DIANA M · CIK 0001887450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 147 Shares and (ii) $283.90 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $3.34. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 21:49 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionRestricted Stock Unit · Derivative | 232 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-009126 · rdgdoc.xml · derivative · entry 3 LANCHONEY DIANA M · CIK 0001887450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,160 Underlying: Common Stock · 232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) [147] Shares and (ii) $352.75 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $4.15. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.exercise_date: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) [147] Shares and (ii) $352.75 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $4.15. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) [147] Shares and (ii) $352.75 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $4.15. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 21:49 UTC | CervoMed Inc. DFFN · Entity 7338 | Disposition to issuerCommon Stock | 85 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-009126 · rdgdoc.xml · nonDerivative · entry 2 LANCHONEY DIANA M · CIK 0001887450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147 F1 · kind: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) [147] Shares and (ii) $352.75 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $4.15. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. F1 · price: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) [147] Shares and (ii) $352.75 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $4.15. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 21:49 UTC | CervoMed Inc. DFFN · Entity 7338 | Exercise / conversionCommon Stock | 232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-009126 · rdgdoc.xml · nonDerivative · entry 1 LANCHONEY DIANA M · CIK 0001887450 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On March 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) [147] Shares and (ii) $352.75 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $4.15. The remainder of award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| July 01, 2021 Filed Oct 16, 2021 00:01 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantRestricted Stock Unit · Derivative | 69,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-023770 · rdgdoc.xml · derivative · entry 3 LANCHONEY DIANA M · CIK 0001887450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,400 Underlying: Common Stock · 69,400 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares underlying the restricted stock units will vest in 6 equal (or as nearly equal as possible) tri-monthly installments on the last calendar day of every third month over an 18-month period beginning on January 1, 2023. F4 · derivative.expiration_date: The shares underlying the restricted stock units will vest in 6 equal (or as nearly equal as possible) tri-monthly installments on the last calendar day of every third month over an 18-month period beginning on January 1, 2023. Read SEC document |
| July 01, 2021 Filed Oct 16, 2021 00:01 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 83,300 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001437749-21-023770 · rdgdoc.xml · derivative · entry 2 LANCHONEY DIANA M · CIK 0001887450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,300 Underlying: Common Stock · 83,300 shares Expires 2031-07-01 F2 · derivative.exercise_date: The shares underlying the options will vest in 18 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over an 18-month period beginning July 1, 2021. Read SEC document |
| July 01, 2021 Filed Oct 16, 2021 00:01 UTC | CervoMed Inc. DFFN · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 83,300 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001437749-21-023770 · rdgdoc.xml · derivative · entry 1 LANCHONEY DIANA M · CIK 0001887450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,300 Underlying: Common Stock · 83,300 shares Expires 2031-07-01 F1 · derivative.exercise_date: The shares underlying the options will vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 12-month period beginning July 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.